Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations

Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195.

To determine the clinical, laboratory and hemodynamic profile in patients with primary pulmonary hypertension and associated portal hypertension, 7 new cases and 71 previously reported cases were analyzed. There was no gender predilection and the average age at diagnosis was 41 years. Liver cirrhosis was the most frequent cause of hypertension (82%) and a surgical portosystemic shunt was present in 29%. Almost invariably, portal hypertension either preceded or was diagnosed concurrently with pulmonary hypertension, favoring the hypothesis that in portal hypertension, the pulmonary vasculature may be exposed to vasoactive substances normally metabolized or produced by the diseased liver, possibly inducing vasoconstriction or direct toxic damage to the pulmonary arteries. Clinically, exertional dyspnea was the most frequent presenting symptom (81%); other symptoms, such as syncope, chest pain and fatigue, were present in less than 33%. An accentuated pulmonary component of the second heart sound (82%) and a systolic murmur (69%) were the most common physical findings. At least 75% of these patients had evidence of pulmonary hypertension on electrocardiography (right ventricular hypertrophy) or roentgenography (cardiomegaly or dilated main pulmonary arteries, or both). Hemodynamic findings included severe pulmonary hypertension (mean pulmonary artery pressure 59 +/- 19 mm Hg) with normal pulmonary capillary wedge pressure and cardiac output. Treatment was basically palliative and the mean and median survival times were 15 and 6 months, respectively. In brief, on the basis of clinical presentation and laboratory features, patients with combined primary pulmonary hypertension and portal hypertension seldom represent a diagnostic challenge. Further research is needed on treatment, which remains palliative. The survival rate is poor and worse than that seen in isolated primary pulmonary hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				J. Le Pavec, R. Souza, P. Herve, D. Lebrec, L. Savale, C. Tcherakian, X. Jais, A. Yaici, M. Humbert, G. Simonneau, et al. Portopulmonary Hypertension: Survival and Prognostic Factors Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 637 - 643. [Abstract] [Full Text] [PDF]

				T. Ohno, J. Muneuchi, K. Ihara, T. Yuge, Y. Kanaya, S. Yamaki, and T. Hara Pulmonary Hypertension in Patients With Congenital Portosystemic Venous Shunt: A Previously Unrecognized Association Pediatrics, April 1, 2008; 121(4): e892 - e899. [Abstract] [Full Text] [PDF]

				K. L. SWANSON and M. J. KROWKA Screen for portopulmonary hypertension, especially in liver transplant candidates Cleveland Clinic Journal of Medicine, February 1, 2008; 75(2): 121 - 136. [Abstract] [Full Text] [PDF]

				M. M. Hoeper, H. J. Seyfarth, G. Hoeffken, H. Wirtz, E. Spiekerkoetter, M. W. Pletz, T. Welte, and M. Halank Experience with inhaled iloprost and bosentan in portopulmonary hypertension Eur. Respir. J., December 1, 2007; 30(6): 1096 - 1102. [Abstract] [Full Text] [PDF]

				C. S. Sigel, T. C. Harper, and L. B. Thorne Postpartum Sudden Death From Pulmonary Hypertension in the Setting of Portal Hypertension Obstet. Gynecol., August 1, 2007; 110(2): 501 - 503. [Abstract] [Full Text] [PDF]

				J. Moorman, M. Saad, S. Kosseifi, and G. Krishnaswamy Hepatitis C Virus and the Lung: Implications for Therapy Chest, October 1, 2005; 128(4): 2882 - 2892. [Abstract] [Full Text] [PDF]

				M. M. Hoeper, M. Halank, C. Marx, G. Hoeffken, H. J. Seyfarth, J. Schauer, J. Niedermeyer, and J. Winkler Bosentan therapy for portopulmonary hypertension Eur. Respir. J., March 1, 2005; 25(3): 502 - 508. [Abstract] [Full Text] [PDF]

				Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF]

				S. Minder, M. Fischler, B. Muellhaupt, M.P. Zalunardo, R. Jenni, P-A. Clavien, and R. Speich Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension Eur. Respir. J., October 1, 2004; 24(4): 703 - 707. [Abstract] [Full Text] [PDF]

				F S Benjaminov, M Prentice, K W Sniderman, S Siu, P Liu, and F Wong Portopulmonary hypertension in decompensated cirrhosis with refractory ascites Gut, September 1, 2003; 52(9): 1355 - 1362. [Abstract] [Full Text]

				R. Budhiraja and P. M. Hassoun Portopulmonary Hypertension: A Tale of Two Circulations Chest, February 1, 2003; 123(2): 562 - 576. [Abstract] [Full Text] [PDF]

				J. W. Chu, P. N. Kao, J. L. Faul, and R. L. Doyle High Prevalence of Autoimmune Thyroid Disease in Pulmonary Arterial Hypertension Chest, November 1, 2002; 122(5): 1668 - 1673. [Abstract] [Full Text] [PDF]

				R. D'Souza, R.J. MacFadyen, F. Kerr, A. Peacock, and M.M. Steven Lessons to be learned: a case study approach A case study of the temporal onset of pulmonary hypertension with pre-existent cirrhotic portal hypertension The Journal of the Royal Society for the Promotion of Health, December 1, 2001; 121(4): 257 - 261. [Abstract] [PDF]

				E Zakynthinos, T Vassilakopoulos, P Kaltsas, E Malagari, Z Daniil, C Roussos, and S G Zakynthinos Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major Thorax, September 1, 2001; 56(9): 737 - 739. [Abstract] [Full Text] [PDF]

				M. Auletta, U. Oliviero, L. Iasiuolo, G. Scherillo, and S. Antoniello Pulmonary Hypertension Associated with Liver Cirrhosis: An Echocardiographic Study Angiology, December 1, 2000; 51(12): 1013 - 1020. [Abstract] [PDF]

				A. L. Rafanan, J. Maurer, A. C. Mehta, and R. Schilz Progressive Portopulmonary Hypertension After Liver Transplantation Treated With Epoprostenol Chest, November 1, 2000; 118(5): 1497 - 1500. [Abstract] [Full Text] [PDF]

				S S SALVI UDCA, PBC, and biochemistry, what does normal mean? Gut, October 1, 2000; 47(4): 595 - 596. [Full Text] [PDF]

				M J KROWKA Hepatopulmonary syndromes Gut, January 1, 2000; 46(1): 1 - 4. [Full Text] [PDF]

				A J Peacock Rare diseases bullet 5: Primary pulmonary hypertension Thorax, December 1, 1999; 54(12): 1107 - 1118. [Full Text]

				C. D. Cool, J. S. Stewart, P. Werahera, G. J. Miller, R. L. Williams, N. F. Voelkel, and R. M. Tuder Three-Dimensional Reconstruction of Pulmonary Arteries in Plexiform Pulmonary Hypertension Using Cell-Specific Markers : Evidence for a Dynamic and Heterogeneous Process of PulmonaryEndothelial Cell Growth Am. J. Pathol., August 1, 1999; 155(2): 411 - 419. [Abstract] [Full Text] [PDF]

				M. Tarquino, R. L. Geggel, R. S. Strauss, J. Rhodes, B. Wunderlich, and R. J. Rohrer Treatment of Pulmonary Hypertension with Inhaled Nitric Oxide During Hepatic Transplantation in an Adolescent: Reversibility of Pulmonary Hypertension After Transplantation Clinical Pediatrics, August 1, 1998; 37(8): 505 - 509. [PDF]